Medical Information

Quviviq, as a dual orexin receptor antagonist, is contraindicated for patients with myasthenia gravis and narcolepsy as it may exacerbate muscle weakness or interfere with arousal regulation mechanisms. The following will explain the mechanism of action, clinical risks, and special precautions to help relevant populations avoid medication risks.

Reasons for contraindications in patients with myasthenia gravis

Dali Leisheng may exacerbate neuromuscular conduction disorders in patients with myasthenia gravis by inhibiting arousal signals by blocking appetite hormone receptors. The disease itself has skeletal muscle fatigue, and drug-induced excessive sedation may further weaken respiratory muscle function and increase the risk of respiratory failure.

2. Prohibition basis for patients with episodic sleep disorders

The characteristic of episodic sleep disorder is abnormal appetite signal pathway, and the antagonistic effect of daliresin on OX1R/OX2R receptors may induce or exacerbate symptoms such as sudden onset and sleep paralysis. Clinical studies have shown that in healthy volunteers, a quasi catabolic reaction has been observed when taking excessive amounts.

(1) Risk associated with impaired respiratory function

Patients with myasthenia gravis often have respiratory muscle weakness, and Dalirasen may reduce ventilatory power through central inhibition. Patients with obstructive sleep apnea also need to be cautious as medication may mask the low oxygen arousal response.

(2) Combination of adverse reactions in the nervous system

Patients with two types of diseases are more sensitive to sedative effects, and the drowsiness and muscle weakness caused by Dali Leisheng may worsen the original symptoms. Elderly patients also need to pay special attention to the risk of falls, and it is recommended to monitor daytime alertness.

3 alternative treatment plan recommendations

For patients with myasthenia gravis or episodic sleep disorders complicated with insomnia, non pharmacological interventions (such as cognitive-behavioral therapy) should be prioritized. If medication is necessary, the risk should be evaluated under the guidance of a neurologist and avoid combination with other central nervous system inhibitors.